{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:04:35Z","timestamp":1791281075901,"version":"4.1.0"},"reference-count":74,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pericardial disease is increasingly recognized in cancer patients, including acute pericarditis, pericardial effusion, and constrictive pericarditis, often indicating a poor prognosis. Acute pericarditis arises from direct tumor involvement, cancer therapies, and radiotherapy. Immune checkpoint inhibitor (ICI)-related pericarditis, though rare, entails significant mortality risk. Treatment includes NSAIDs, colchicine, and corticosteroids or anti-IL1 drugs in refractory cases. Pericardial effusion is the most frequent manifestation, primarily caused by lung cancer, followed by breast cancer, lymphoma, leukemia, gastrointestinal tumors, and melanoma. Chemotherapy, immunotherapy, and radiotherapy may also cause fluid accumulation in the pericardial space. Symptomatic relief for pericardial effusion may require pericardiocentesis, prolonged catheter drainage, or a pericardial window. Instillation of intrapericardial cytostatic agents may reduce recurrence. Constrictive pericarditis, though less common, often develops from radiotherapy and requires multimodality imaging for diagnosis, with pericardiectomy as the definitive treatment. Primary pericardial tumors are rare, with metastases being more frequent. Patients with cancer and pericardial disease generally have poor survival, emphasizing the need for early detection. A multidisciplinary approach involving hematologists, oncologists, and cardiologists is crucial to tailoring pericardial disease treatment to a patient\u2019s clinical status, thereby improving the quality of life and prognosis.<\/jats:p>","DOI":"10.3390\/cancers16203466","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T06:46:33Z","timestamp":1728888393000},"page":"3466","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Pericardial Disease in Patients with Cancer: Clinical Insights on Diagnosis and Treatment"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0066-0573","authenticated-orcid":false,"given":"Laia","family":"Lorenzo-Esteller","sequence":"first","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7475-4145","authenticated-orcid":false,"given":"Ra\u00fal","family":"Ramos-Polo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Pons Riverola","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herminio","family":"Morillas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Berdejo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1485-5080","authenticated-orcid":false,"given":"Sonia","family":"Pernas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Pomares","sequence":"additional","affiliation":[{"name":"Clinical Haematology Department, Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6941-0575","authenticated-orcid":false,"given":"Leyre","family":"Asiain","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garay","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Mart\u00ednez P\u00e9rez","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Jim\u00e9nez-Marrero","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-7880","authenticated-orcid":false,"given":"Lidia","family":"Alcoberro","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9674-5554","authenticated-orcid":false,"given":"Ernest","family":"Nadal","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Preclinical and Experimental Research in Thoracic Tumors (PRETT), Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gubern-Prieto","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gual-Capllonch","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari Son Espases, 07120 Palma, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarna","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Enjuanes","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-720X","authenticated-orcid":false,"given":"Josep","family":"Comin-Colet","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain"},{"name":"Department of Clinical Sciences, School of Medicine, Universitat de Barcelona (UB), L\u2019Hospitalet de Llobregat, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5511-8597","authenticated-orcid":false,"given":"Pedro","family":"Moliner","sequence":"additional","affiliation":[{"name":"Cardiology Department, Bellvitge University Hospital, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Cardio-Oncology Unit, Bellvitge University Hospital\u2014Catalan Institute of Oncology, L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Bio-Heart Cardiovascular, Respiratory and Systemic Diseases and Cellular Aging Program, Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF01626346","article-title":"Metastatic and Invasive Tumours Involving the Heart in a Geriatric Population: A Necropsy Study","volume":"419","author":"MacGee","year":"1991","journal-title":"Vichows Archiv. A Pathol. Anat."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/j.jtcvs.2014.04.031","article-title":"Systemic Chemotherapy in Combination with Pericardial Window Has Better Outcomes in Malignant Pericardial Effusions","volume":"148","author":"Lestuzzi","year":"2014","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.lungcan.2010.10.013","article-title":"Neoplastic Pericardial Disease in Lung Cancer: Impact on Outcomes of Different Treatment Strategies. A Multicenter Study","volume":"72","author":"Lestuzzi","year":"2011","journal-title":"Lung Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjcard.2020.12.092","article-title":"Pericardial Involvement in Cancer","volume":"145","author":"Chahine","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/heartjnl-2019-315852","article-title":"Pericardial Diseases in Patients with Cancer: Contemporary Prevalence, Management and Outcomes","volume":"106","author":"Imazio","year":"2020","journal-title":"Heart"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/clc.20936","article-title":"Neoplastic Pericardial Effusion","volume":"34","author":"Refaat","year":"2011","journal-title":"Clin. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pons-Riverola, A., Morillas, H., Berdejo, J., Pernas, S., Pomares, H., Asiain, L., Garay, A., Fernandez-Ortega, A., Oliveira, A.C., and Mart\u00ednez, E. (2023). Developing Cardio-Oncology Programs in the New Era: Beyond Ventricular Dysfunction Due to Cancer Treatments. Cancers, 15.","DOI":"10.3390\/cancers15245885"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Moliner, P., and L\u00f3pez-Fern\u00e1ndez, T. (Rev. Esp. Cardiol., 2024). Spanish Society of Cardiology (SEC) Scientific Committee for the accreditation of cardio-oncology-hematology units Certification of Cardio-Oncology-Hematology Programs: An Opportunity to Improve the Quality of Care for Patients with Cancer, Rev. Esp. Cardiol., in press.","DOI":"10.1016\/j.rec.2024.04.013"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and Outcomes of a Cardio-Oncology Service in the United Kingdom-a Five-Year Experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jama.2015.12763","article-title":"Evaluation and Treatment of Pericarditis: A Systematic Review","volume":"314","author":"Imazio","year":"2015","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/CIRCULATIONAHA.116.024041","article-title":"Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality","volume":"136","author":"Farkas","year":"2017","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000093528","article-title":"Pericarditis after High-Dose Chemotherapy: More Frequent than Expected?","volume":"29","author":"Bock","year":"2006","journal-title":"Oncol. Res. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the Task Force on Cardio-Oncology of the European Society of Cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1177\/1078155219865934","article-title":"Ivosidenib Induction Therapy Complicated by Myopericarditis and Cardiogenic Shock: A Case Report and Literature Review","volume":"26","author":"Patel","year":"2020","journal-title":"J. Oncol. Pharm. Pract"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Konstantinidis, I., Tsokkou, S., Grigoriadis, S., Chrysavgi, L., and Gavriilaki, E. (2024). Cardiotoxicity in Acute Myeloid Leukemia in Adults: A Scoping Study. Cancers, 16.","DOI":"10.3390\/cancers16132474"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/raon-2018-0035","article-title":"Pericardial Disease after Breast Cancer Radiotherapy","volume":"53","author":"Marinko","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11936-018-0654-7","article-title":"Pericardial Disease in Cancer Patients","volume":"20","author":"Ghosh","year":"2018","journal-title":"Curr. Treat. Opt. Cardiovasc. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases","volume":"36","author":"Adler","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.radonc.2010.08.010","article-title":"Late Radiation-Induced Heart Disease after Radiotherapy. Clinical Importance, Radiobiological Mechanisms and Strategies of Prevention","volume":"100","author":"Andratschke","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG), Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., Cutter, D., Davies, C., and Ewertz, M. (2011). Effect of Radiotherapy after Breast-Conserving Surgery on 10-Year Recurrence and 15-Year Breast Cancer Death: Meta-Analysis of Individual Patient Data for 10,801 Women in 17 Randomised Trials. Lancet, 378, 1707\u20131716.","DOI":"10.1016\/S0140-6736(11)61629-2"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1515\/raon-2018-0008","article-title":"Voluntary Deep Inspiration Breath-Hold Reduces the Heart Dose without Compromising the Target Volume Coverage during Radiotherapy for Left-Sided Breast Cancer","volume":"52","author":"Caparrotti","year":"2018","journal-title":"Radiol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial Disease in Patients Treated with Immune Checkpoint Inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaccas.2019.11.080","article-title":"Myocardial and Pericardial Toxicity Associated with Immune Checkpoint Inhibitors in Cancer Patients","volume":"2","author":"Chahine","year":"2020","journal-title":"JACC Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","article-title":"Immune Checkpoint Inhibitors-Associated Pericardial Disease: A Systematic Review of Case Reports","volume":"70","author":"Inno","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11886-019-1225-6","article-title":"Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management","volume":"21","author":"Ala","year":"2019","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12410-017-9400-x","article-title":"Novel Noninvasive Nuclear Medicine Imaging Techniques for Cardiac Inflammation","volume":"10","author":"Kircher","year":"2017","journal-title":"Curr. Cardiovasc. Imaging Rep."},{"key":"ref_28","unstructured":"(2024, May 27). Management of Acute and Recurrent Pericarditis. Available online: https:\/\/www.jacc.org\/doi\/epdf\/10.1016\/j.jacc.2019.11.021."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.2016.15826","article-title":"Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial","volume":"316","author":"Brucato","year":"2016","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e021685","DOI":"10.1161\/JAHA.121.021685","article-title":"Emerging Therapies for Recurrent Pericarditis: Interleukin-1 Inhibitors","volume":"10","author":"Elajami","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40959-024-00207-3","article-title":"Pericardial Effusion in Oncological Patients: Current Knowledge and Principles of Management","volume":"10","author":"Mori","year":"2024","journal-title":"Cardio-Oncology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2019.07.001","article-title":"Current Management of Symptomatic Pericardial Effusions in Cancer Patients","volume":"1","author":"Besnard","year":"2019","journal-title":"JACC Cardio Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11886-018-1040-5","article-title":"Pericardial Disease Associated with Malignancy","volume":"20","author":"Schusler","year":"2018","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.amjcard.2005.01.094","article-title":"Relation of Acute Pericardial Disease to Malignancy","volume":"95","author":"Imazio","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2015.11.023","article-title":"Cause and Long-Term Outcome of Cardiac Tamponade","volume":"117","author":"Vivas","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_36","first-page":"OE01","article-title":"Acute Cyclophosphamide Hemorrhagic Myopericarditis: Dilemma Case Report, Literature Review and Proposed Diagnostic Criteria","volume":"9","author":"Wadia","year":"2015","journal-title":"J. Clin. Diagn Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101345","DOI":"10.1016\/j.cpcardiol.2022.101345","article-title":"Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database","volume":"47","author":"Janus","year":"2022","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_38","first-page":"853","article-title":"Acute Pleural and Pericardial Effusion Induced by Chemotherapy in Treating Chronic Myelocytic Leukemia","volume":"60","author":"He","year":"2014","journal-title":"Clin. Lab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive Pleural and Pericardial Effusion in Chronic Myeloid Leukemia during Treatment with Dasatinib at 100 Mg or 50 Mg Daily","volume":"96","author":"Krauth","year":"2011","journal-title":"Haematologica"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1517\/14740331003742935","article-title":"Pleural\/Pericardic Effusions during Dasatinib Treatment: Incidence, Management and Risk Factors Associated to Their Development","volume":"9","author":"Breccia","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e071456","DOI":"10.1136\/bmjopen-2022-071456","article-title":"Fluid Retention-Associated Adverse Events in Patients Treated with BCR::ABL1 Inhibitors Based on FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study","volume":"13","author":"Huang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_42","first-page":"142","article-title":"Dasatinib Induced Pleuro-Pericardial Effusion","volume":"91","author":"Mishra","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijrobp.2017.05.022","article-title":"Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer","volume":"99","author":"Ning","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of Immune Checkpoint Inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_45","first-page":"6","article-title":"Managing Cardiotoxicity Associated with Immune Checkpoint Inhibitors","volume":"5","author":"Upadhrasta","year":"2019","journal-title":"Chronic Dis. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CJI.0000000000000217","article-title":"Immune-Mediated Pericarditis with Pericardial Tamponade During Nivolumab Therapy","volume":"41","author":"Gomes","year":"2018","journal-title":"J. Immunother."},{"key":"ref_47","first-page":"794842","article-title":"Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication","volume":"2015","author":"Yun","year":"2015","journal-title":"Case Rep. Oncol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000447053","article-title":"Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion","volume":"136","author":"Kushnir","year":"2016","journal-title":"Cardiology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent Pleural Effusions and Cardiac Tamponade as Possible Manifestations of Pseudoprogression Associated with Nivolumab Therapy\u2013 a Report of Two Cases","volume":"4","author":"Kolla","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","article-title":"Targeted Cancer Therapies with Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors","volume":"123","author":"Palaskas","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2009.08.010","article-title":"Chylothorax: Aetiology, Diagnosis and Therapeutic Options","volume":"104","author":"McGrath","year":"2010","journal-title":"Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1097\/CCM.0b013e31824e1865","article-title":"Oncologic Emergencies","volume":"40","author":"McCurdy","year":"2012","journal-title":"Crit. Care Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1477-7819-12-249","article-title":"Prognostic Factors Affecting Survival of Patients with Cancer-Related Pericardial Effusion Managed by Surgery","volume":"12","author":"Jeon","year":"2014","journal-title":"World J. Surg. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10741-012-9327-x","article-title":"Diagnostic Value of Biochemical Biomarkers in Malignant and Non-Malignant Pericardial Effusion","volume":"18","author":"Karatolios","year":"2013","journal-title":"Heart Fail Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2015.06.1332","article-title":"Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion","volume":"66","author":"Iliescu","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative Management of Nivolumab-Induced Pericardial Effusion: A Case Report and Review of Literature","volume":"7","author":"Shaheen","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e3273","DOI":"10.1097\/MD.0000000000003273","article-title":"Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion","volume":"95","author":"Numico","year":"2016","journal-title":"Medicine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/icvts\/ivu267","article-title":"Palliative Treatment for Symptomatic Malignant Pericardial Effusion","volume":"19","author":"Jama","year":"2014","journal-title":"Interact. CardioVasc. Thorac. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"295","DOI":"10.31083\/j.rcm2410295","article-title":"Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review","volume":"24","author":"Fioretti","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/heartjnl-2015-307907","article-title":"Systematic Review of Percutaneous Interventions for Malignant Pericardial Effusion","volume":"101","author":"Virk","year":"2015","journal-title":"Heart"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/17843286.2020.1790180","article-title":"Malignant Cardiac Tamponade: Safety and Efficacy of Intrapericardial Bleomycin Instillation","volume":"77","author":"Defruyt","year":"2022","journal-title":"Acta Clin. Belg."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.1996.14.12.3141","article-title":"Prospective Comparison of the Sclerosing Agents Doxycycline and Bleomycin for the Primary Management of Malignant Pericardial Effusion and Cardiac Tamponade","volume":"14","author":"Liu","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.recesp.2012.09.018","article-title":"Pericardiotom\u00eda percut\u00e1nea con bal\u00f3n como tratamiento inicial del derrame peric\u00e1rdico grave de origen tumoral","volume":"66","author":"Moreno","year":"2013","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jacc.2020.08.003","article-title":"Effect of Anti-Inflammatory Drugs on Clinical Outcomes in Patients with Malignant Pericardial Effusion","volume":"76","author":"Kim","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","first-page":"1092","article-title":"Constrictive Pericarditis: Etiologic Spectrum, Patterns of Clinical Presentation, Prognostic Factors, and Long-Term Follow-Up","volume":"68","year":"2015","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/CIRCULATIONAHA.111.018580","article-title":"Risk of Constrictive Pericarditis after Acute Pericarditis","volume":"124","author":"Imazio","year":"2011","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1161\/CIRCIMAGING.113.001613","article-title":"Echocardiographic Diagnosis of Constrictive Pericarditis","volume":"7","author":"Welch","year":"2014","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/heartjnl-2017-311683","article-title":"Constrictive Pericarditis: Diagnosis, Management and Clinical Outcomes","volume":"104","author":"Welch","year":"2018","journal-title":"Heart"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.euje.2006.03.003","article-title":"Clinical Features of Mixed Physiology of Constriction and Restriction: Echocardiographic Characteristics and Clinical Outcome","volume":"8","author":"Yamada","year":"2007","journal-title":"Eur. J. Echocardiogr."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1136\/heartjnl-2020-316898","article-title":"Anakinra for Constrictive Pericarditis Associated with Incessant or Recurrent Pericarditis","volume":"106","author":"Andreis","year":"2020","journal-title":"Heart"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaccao.2020.05.009","article-title":"Cardiac Tumors: JACC CardioOncology State-of-the-Art Review","volume":"2","author":"Tyebally","year":"2020","journal-title":"JACC Cardio Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/clc.22295","article-title":"Primary Malignancies of the Heart and Pericardium","volume":"37","author":"Burazor","year":"2014","journal-title":"Clin. Cardiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.cllc.2018.11.008","article-title":"Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases","volume":"20","author":"McGehee","year":"2019","journal-title":"Clin. Lung Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/20\/3466\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:12:22Z","timestamp":1760112742000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/20\/3466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":74,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["cancers16203466"],"URL":"https:\/\/doi.org\/10.3390\/cancers16203466","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,12]]}}}